SCHEMBL6801919

SCHEMBL6801919

CCOC(=O)c1cc2c(C)cc(O)c3c2n1CCCCC3=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
GAA P10253 2/20 0.42
ALOX15 P16050 2/20 0.42
MAPK1 P28482 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
BRD4 O60885 1/20 0.39
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
USP2 O75604 1/20 0.38
CYP3A4 P08684 1/20 0.38
PDE3B Q13370 4/20 0.37
PDE3A Q14432 4/20 0.37
NPSR1 Q6W5P4 1/20 0.36
ESR1 P03372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7954130 0.81 ALDH1A1 (0.45) ALDH1A1GAAALOX15MAPK1MEN1
SCHEMBL7958083 0.79 PDE3B (0.39) ALDH1A1GAAALOX15MAPK1MEN1
SCHEMBL7955932 0.78 ALDH1A1 (0.43) ALDH1A1GAAALOX15MAPK1MEN1
SCHEMBL7955774 0.77 MAPK1 (0.43) ALDH1A1GAAALOX15MAPK1MEN1
SCHEMBL7958065 0.75 ALDH1A1 (0.44) ALDH1A1GAAALOX15MAPK1MEN1
SCHEMBL7955709 0.73 ALDH1A1 (0.42) ALDH1A1GAAALOX15MAPK1MEN1
SCHEMBL7954102 0.73 MAPK1 (0.54) ALDH1A1GAAALOX15MAPK1MEN1
SCHEMBL7946960 0.72 KCNK3 (0.41) ALDH1A1GAAALOX15MAPK1MEN1
SCHEMBL7954146 0.72 KDM4E (0.41) ALDH1A1GAAALOX15MAPK1MEN1
SCHEMBL7946972 0.72 ALDH1A1 (0.43) ALDH1A1GAAALOX15MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734205-B2 SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2004-05-11 US disclosed
US-20030018056-A1 Substituted guanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2003-01-23 US disclosed
EP-1238971-A1 SUBSTITUTED GUANIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018056-A1 Substituted guanidine derivatives SLC28A1, SLC7A1, ABCB11 ALDH1A1 1321/4885GAA 292/4885ALOX15 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.